Advertisement

Picture BIO Deutschland German Corona Special 2021 Digital 650x80px
All >

Deals > Germany

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Germany or involving German organisations.

Total search results: 1557 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Stimit–Dräger: investment, 202104 acquisition of majority share in Stimit AG by Drägerwerk AG & Co KGaA 2021-04-01
Cytosurge–Univ Tübingen: genome editing, 202103 collab cell line developm using FluidFM nano-injection for single cell CRISPR gene engineering 2021-03-24
Formycon–Leukocare: biopharmaceuticals, 202103– collab Master Service Agreem developm stable formulations for biosimilars/biologics of Formycon 2021-03-24
Indivumed–Live Wire Strategic Communications: public relations, 202103 service existent by Live Wire 2021-03-18
AgomAb Therapeutics–Boehringer: investment, 202103 financing round Series B totalling $74m incl existing + co-investor BIVF 2021-03-10
AgomAb Therapeutics–Trophic Communications: public relations, 202103 service existent by Trophic Communications 2021-03-10
BellaSeno–Akampion: public relations, 202103 service existent by Akampion 2021-03-10
BellaSeno–Fraunhofer: implant production technology, 202103– collab developm automated resorbable implant production + QC with Fraunhofer IPT 2021-03-10
BellaSeno–Germany (govt): grant, 202103– KUM-innovativ grant totalling €1.4m tog with Fraunhofer IPT from BMBF 2021-03-10
Lophius–Mikrogen: investment, 202103 acquisition of assets + technologies incl takeover of entire team + lab in Regensburg by Mikrogen 2021-03-08
Atai Life Sciences–KCSA Strategic Communications: public relations, 202103 service existent KCSA is media contact 2021-03-03
Atai Life Sciences–SEVERAL: investment, 202103 financing round Series D $157m co-led by Apeiron + Thiel Capital 2021-03-03
ActiTrexx–SEVERAL: investment, 202103 financing round Series A €3.5m led by LBBW Venture Capital GmbH 2021-03-02
Kairos GmbH–Iqvia: investment, 202103 acquisition of Kairos GmbH by Iqvia 2021-03-01
InfanDx–Akampion: public relations, 202102 service existent by Akampion 2021-02-04
Genopis–Wacker: investment, 202102 acquisition of Genopis Inc for $39m in cash + milestones from Helixmith Co Ltd + Medivate Partners LLC 2021-02-03
Carisma Therapeutics–Cevec: cell line technology, 202102– license €na for use of CAP technology to produce adenovirus vectors for cancer cell therapy 2021-02-02
Avacta–Bruker: MS-based SARS-CoV-2 test, 202101– collab developm of BAMS SARS-CoV-2 assay on Bruker MALDI-TOF as IVD test 2021-01-28
GeneQuine–Brandenburg (govt): grant, 202101 grant €900k from investment bank of federal state Brandenburg 2021-01-26
GeneQuine–High-Tech Gründerfonds: investment, 202101 financing round Series A totalling €5.4m incl existing + co-investor HTGF 2021-01-26
GeneQuine–Noshaq: investment, 202101 financing round Series A totalling €5.4m incl co-investor Noshaq SA 2021-01-26
GeneQuine–Pacira BioSciences: credit, 202101 convertible loans totalling €2.75m from Pacira + Samum Vermögensverwaltungs GmbH 2021-01-26
GeneQuine–Pacira BioSciences: investment, 202101 financing round Series A totalling €5.4m incl lead investor Pacira BioSciences 2021-01-26
GeneQuine–Samum: credit, 202101 convertible loans totalling €2.75m from Pacira BioSciences Inc + Samum Vermögensverwaltungs GmbH 2021-01-26
GeneQuine–Samum: investment, 202101 financing round Series A totalling €5.4m incl co-investor Samum Vermögensverwaltungs GmbH 2021-01-26
GeneQuine–SEVERAL: investment, 202101 financing round Series A €5.4m led by Pacira BioSciences 2021-01-26
i3 Membrane–High-Tech Gründerfonds: investment, 202101 financing round totalling 7-figure € sum inkl existing investor HTGF 2021-01-25
i3 Membrane–OTHER: investment, 202101 financing round totalling 7-figure € sum incl three private investors 2021-01-25
i3 Membrane–SEVERAL: investment, 202101 financing round 7-figure € sum from HTGF + three private investors 2021-01-25
Numares–Bruker: NMR spectroscopy, 202102– collab developm + product integration Axinon platform for metabolomics-based NMR-CDx 2021-01-21
AdVita Lifescience–Relief Therapeutics: investment, 202001– binding term sheet acquisition 100% of AdVita for €25m in shares + €20m Milestones 2021-01-20
Relief Therapeutics–MC Services: public relations, 202101 service existent by MC Services 2021-01-20
LignoPure–Hamburg (govt): investment, 202101 seed financing round totalling €2.2m incl investor Innovationsstarter Fonds Hamburg GmbH 2021-01-18
LignoPure–High-Tech Gründerfonds: investment, 202101 seed financing round totalling €2.2m incl investor HTGF 2021-01-18
LignoPure–SEVERAL: investment, 202101 seed financing round €2.2m from HTGF + IFH + Tanovis AG 2021-01-18
LignoPure–Tanovis: investment, 202101 seed financing round totalling €2.2m incl investor Tanovis AG 2021-01-18
Medigene–LifeSci: public relations, 202101 supply service existent by LifeSci Advisors 2021-01-13
Affimed–SEVERAL: investment, 202101 public offering $100m+$15m with 16.7m+2.5m common shares at $6/share 2021-01-12
Affimed–SVB: credit, 202101–202511 up to €25m loans in three tranches with €10m at closing plus €15m milestone-based 2021-01-11
Labforward–2mag: investment, 202101 financing round Series B totalling >€5m incl new + co-investor 2mag 2021-01-11
Labforward–Peppermint: investment, 202101 financing round Series B totalling >€5m incl existing + co-investor Peppermint VenturePartners 2021-01-11
Labforward–SEVERAL: investment, 202101 financing round Series B >€5m led by Tecan + incl 2mag + Peppermint VenturePartners 2021-01-11
Labforward–Tecan: investment, 202101 financing round Series B totalling >€5m incl €4m from new + lead investor Tecan resulting in 10% stake 2021-01-11
Biogen–Cevec: cell line technology, 202101– license €na to Elevecta technology for manufacutring of AAV vectors for gene therapies 2021-01-08
AmpTec–Merck (DE): investment, 202101 acquisition €na of AmpTec GmbH bei Merck 2021-01-07
BioGeneration Ventures–Germany (govt): investment, 202101 final closing of BGV IV totalling €140m incl investor KfW Capital 2021-01-07
Cellectis–Sirion Biotech: cell/gene therapy manufacturing technology, 202101– non-excl license €na to LentiBoost technology for CAR-T cell therapies 2021-01-07
Sterna Biologicals–SEVERAL: investment, 202101 financing round Series A 2nd closing €10m bringing total Series A to €22m 2021-01-07
Eleva–Zukunftsfonds Heilbronn: investment, 202101– up to €60m for development of CPV-101 2021-01-06
Somatex Medical Technologies–Hologic: investment, 202101 acquisition $64m of Somatex by Hologic 2021-01-04
Biosun Biochemicals–BRAIN: investment, 202101 acquisition 100% €na by BRAIN AG 2021-01-01
MYR GmbH–Gilead Sciences: investment, 202012 acquisition €1.15b in cash + €300m milestones of MYR GmbH by Gilead Sciences Inc 2020-12-10
NBE Therapeutics–Boehringer: investment, 202012– acquisition up to €1.18b by Boehringer 2020-12-10
Resolve Biosciences–Alafi Capital: investment, 202012 financing round Series A totalling $24m incl co-investor Alafi Capital 2020-12-10
Resolve Biosciences–Bioscribe: public relations, 202012 service existent by Bioscribe 2020-12-10
Resolve Biosciences–High-Tech Gründerfonds: investment, 202012 financing round Series A totalling $24m incl co-investor HTGF 2020-12-10
Resolve Biosciences–MasterMind Advisory Services: investment, 202012 financing round Series A totalling $24m incl co-lead investor MasterMind 2020-12-10
Resolve Biosciences–PERSON: investment, 202012 financing round Series A totalling $24m incl co-investor John Shoffner 2020-12-10
Resolve Biosciences–PS Capital Management: investment, 202012 financing round Series A totalling $24m incl co-lead investor PS Capital 2020-12-10
Resolve Biosciences–SEVERAL: investment, 202012 financing round Series A $24m co-led by PS Capital Management + MasterMind Advisory Services 2020-12-10
Curexsys–Evotec: investment, 202012 seed financing round totalling €8.2m incl Evotec acquiring 37% equity stake 2020-12-09
Curexsys–Sartorius: investment, 202012 seed financing round totalling €8.2m incl Sartorius acquiring 21% equity stake 2020-12-09
Curexsys–SEVERAL: investment, 202012 seed financing round €8.2m led by Evotec + Sartorius 2020-12-09
Biomes NGS–GPS Ventures: investment, 202012 pre-series A investment €2m from GPS Ventures GmbH 2020-12-07
Boehringer–Proxygen: molecular glue degraders, 202012– collab + license agreem developm in combi with PROTACs against oncogenic targets 2020-12-07
Adrenomed–HBM: investment, 202011 financing round Series E totalling €22.2m incl existing + co-lead investor HBM Healthcare Investments 2020-11-30
Adrenomed–SEVERAL: investment, 202011 financing round Series E €22.2m co-led by Wellington Partners + HBM 2020-11-30
Adrenomed–Wellington Partners: investment, 202011 financing round Series E totalling €22.2m incl existing + co-lead investor Wellington Partners 2020-11-30
BioNTech–InstaDeep: AI-based drug discovery, 2019– collab initiated in 2019 2020-11-25
BioNTech–InstaDeep: AI-based drug discovery, 202011– strategic collab incl joined AI Innovation Lab to develop immunotherapies 2020-11-25
Emergence Therapeutics–High-Tech Gründerfonds: investment, 202011 follow-on seed financing round incl lead investor HTGF 2020-11-25
Emergence Therapeutics–SEVERAL: investment, 202011 follow-on seed financing round led by HTGF 2020-11-25
Innatera Nanosystems–btov Partners: investment, 202011 seed financing round totalling €5m incl co-lead investor btov Industrial Technologies Fund 2020-11-25
Innatera Nanosystems–MIG Fonds: investment, 202011 seed financing round totalling €5m incl co-lead investor MIG Verwaltungs AG 2020-11-25
Atai Life Sciences–SEVERAL: investment, 202011 financing round Series C $125m incl $32m converted debt co-led by Apeiron + Peter Thiel + Catalio 2020-11-23
m2p-labs–Danaher: investment, 202011 acquisition of m2p-biolabs by Beckman Coulter Life Sciences 2020-11-12
MorphoSys–Cherry Biolabs: Hemibody technology, 202011– license €na to apply Hemibody technology to six exclusive targets 2020-11-11
Catalym–Bavaria (govt): investment, 202011 financing round Series B totalling €50m incl co-investor Wachstumsfonds Bayern 2020-11-10
Catalym–Germany (govt): investment, 202011 financing round Series B totalling €50m incl co-investor Coparion 2020-11-10
Catalym–Novartis: investment, 202011 financing round Series B totalling €50m incl co-investor Novartis Venture Fund 2020-11-10
Catalym–SEVERAL: investment, 202011 financing round Series B €50m led by Vesalius Biocapital III 2020-11-10
Catalym–Vesalius Biocapital: investment, 202011 financing round Series B totalling €50m incl lead investor Vesalius Biocapital III 2020-11-10
Roche–Cevec: cell line technology, 202011– license €na to Elevecta technology for manufacutring of AAV vectors for gene therapies 2020-11-10
Vera Therapeutics–Merck (DE): investment, 202011 Merck reveices 10% equity in Vera Tx as part of license deal for atacicept 2020-11-09
Polaris Science (SG)–Nynomic: plant phenotyping, 202011– distribution in Singapore + Malaysia of LemnaTec solutions for phenotyping + seed testing 2020-11-01
TVM–Lilly: investment, 202010 final closing totalling $478m of fund TVM Life Science Innovation II incl investor Eli Lilly 2020-10-27
TVM–OCP Capital: investment banking, –202010 supply service OCP supports fund raising for $478m TMV LSI II fund 2020-10-27
TVM–SEVERAL: investment, 202010 final closing of $478m of fund TVM Life Science Innovation II incl Eli Lilly 2020-10-27
AskBio–Bayer: investment, 202010 acquisition by Bayer for $2b upfront plus $2b milestones 2020-10-26
Eternygen–SEVERAL: investment, 202010 financing round Series A2 1st closing €5m led by Evotec 2020-10-26
MD Biosciences–MLM Medical Labs: investment, 202010 acquisition of MD Biosciences Inc by MLM Medical Labs 2020-10-26
ChromoTek–Proteintech: investment, 202010 acquisition of ChromoTek by Proteintech Group 2020-10-20
Topas Therapeutics–BioMedPartners: investment, 202010 financing round Series B totalling €22m incl new + co-lead investor BioMedPartners 2020-10-19
Topas Therapeutics–Boehringer: investment, 202010 financing round Series B totalling €22m incl existing + co-investor BIVF 2020-10-19
Topas Therapeutics–EMBL: investment, 202010 financing round Series B totalling €22m incl existing + co-investor EMBL Ventures 2020-10-19
Topas Therapeutics–Epidarex Capital: investment, 202010 financing round Series B totalling €22m incl existing + co-investor Epidarex Capital 2020-10-19
Topas Therapeutics–Evotec: investment, 202010 financing round Series B totalling €22m incl existing + co-investor Evotec 2020-10-19
Topas Therapeutics–Gimv: investment, 202010 financing round Series B totalling €22m incl existing + co-investor Gimv 2020-10-19
Topas Therapeutics–SEVERAL: investment, 202010 financing round Series B €22m co-led by Vesalius + BioMedPartners plus all existing investors 2020-10-19
Topas Therapeutics–Vesalius Biocapital: investment, 202010 financing round Series B totalling €22m incl new + co-lead investor Vesalius Biocapital III 2020-10-19
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16  next pagenext page



Advertisement

Picture Berlin Partner Hotspot for Startups 650x80px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [iito] No Content Marketing 650x80px

» top